Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Oncolytics Enters into Sponsorship Agreement with NCIC CTG

Published: Friday, May 04, 2012
Last Updated: Thursday, May 03, 2012
Bookmark and Share
Agreement at Queen's University for randomized phase II study in colorectal cancer.

Oncolytics Biotech Inc. has announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic colorectal cancer.

"We are pleased to be conducting a second randomized study with the NCIC CTG," said Dr. Brad Thompson, President and CEO of Oncolytics.

Dr. Thompson continued, "This study will build on both our early preclinical and clinical colorectal cancer work, as well as preclinical research combining REOLYSIN with Avastin®. As a Company, we intend to continue expanding our clinical program to include randomized studies of frequently diagnosed cancers."

The study will be an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with FOLFOX-6 plus bevacizumab (Avastin) versus FOLFOX-6 plus bevacizumab alone.

Approximately 50 response evaluable patients will be enrolled in each arm, after a six to nine patient safety run in.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncolytics Collaborators Present Preclinical Research on Liver Cancer
Dr. Adel Jebar has presented a poster at the 8th Annual International Conference on Oncolytic Virus in UK.
Tuesday, April 15, 2014
Oncolytics Collaborators Present at UK Oncolytic Virus Conference
Collaborators present translational brain cancer clinical data and immunomodulatory preclinical research.
Tuesday, April 15, 2014
Oncolytics Collaborators to Present Preclinical Research in Multiple Myeloma and Melanoma
Research collaborators will make two poster presentations at the AACR 2014 Annual Meeting.
Tuesday, April 08, 2014
Oncolytics Biotech® Announces Third Quarter 2013 Results
Company announces its financial results and operational highlights.
Monday, November 11, 2013
Oncolytics Biotech® Announces Addition to Senior Management Team
Appointment of Dr. Jeremy Grushcow to the role of General Counsel.
Monday, September 16, 2013
Oncolytics Announces Positive Final Tumour Response Data for U.S. Phase 2 Study of REOLYSIN®
Final progression-free survival and safety data for the study will be reported later in 2013.
Tuesday, September 10, 2013
Oncolytics Meets Primary Endpoint in U.S. Phase 2 Study of REOLYSIN®
Company has met primary overall statistical endpoint in U.S. Phase 2 clinical trial in SCCLC patients.
Tuesday, May 28, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial
Company announces preliminary results from trial in patients using intravenous administration of REOLYSIN®.
Monday, May 27, 2013
Oncolytics Announces 2012 Year End Results
Company has completed two financings over the last 14 months raising gross proceeds in excess of $50 million.
Tuesday, March 19, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase II Clinical Trial
Investigating REOLYSIN® in combination with gemcitabine in patients with advanced or metastatic pancreatic cancer.
Thursday, February 21, 2013
Oncolytics Announces Additional Positive REOLYSIN® Clinical Trial Data from Phase 2 Study
Study enroll patients with metastatic or recurrent squamous cell carcinoma of the lung.
Monday, February 11, 2013
Oncolytics Meets Primary Endpoint for First Stage of U.S. Phase 2 SCLC Clinical Trial
Primary objective of the trial is to assess the antitumor effect of the treatment regimen.
Friday, February 01, 2013
Oncolytics Completes Patient Enrollment in U.S. Phase I Clinical Trial
Phase I clinical trial investigate REOLYSIN® in combination with FOLFIRI in patients with colorectal cancer.
Monday, August 27, 2012
Oncolytics Announces Second Quarter 2012 Results
Company announces completion of enrollment in the first, 80-patient stage of Phase III clinical trial in head and neck cancers.
Monday, August 06, 2012
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
Agreement for randomized phase II study in advanced and metastatic breast cancers.
Friday, June 22, 2012
Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos